0001178913-22-002173.txt : 20220525
0001178913-22-002173.hdr.sgml : 20220525
20220525160350
ACCESSION NUMBER: 0001178913-22-002173
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220524
FILED AS OF DATE: 20220525
DATE AS OF CHANGE: 20220525
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Maryles Joel Michael
CENTRAL INDEX KEY: 0001850990
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38807
FILM NUMBER: 22962865
MAIL ADDRESS:
STREET 1: 5 ATZMON ST.
CITY: HASHMONAIM
STATE: L3
ZIP: 7312700
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Chemomab Therapeutics Ltd.
CENTRAL INDEX KEY: 0001534248
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 813676773
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: KIRYAT ATIDIM, BUILDING 7
CITY: TEL AVIV
STATE: L3
ZIP: 6158002
BUSINESS PHONE: 972-77-331-0156
MAIL ADDRESS:
STREET 1: KIRYAT ATIDIM, BUILDING 7
CITY: TEL AVIV
STATE: L3
ZIP: 6158002
FORMER COMPANY:
FORMER CONFORMED NAME: Anchiano Therapeutics Ltd.
DATE OF NAME CHANGE: 20180906
FORMER COMPANY:
FORMER CONFORMED NAME: BioCancell Ltd.
DATE OF NAME CHANGE: 20111104
4
1
zk2227908.xml
X0306
4
2022-05-24
0
0001534248
Chemomab Therapeutics Ltd.
CMMB
0001850990
Maryles Joel Michael
5 ATZMON ST.
HASHMONAIM
L3
7312700
ISRAEL
1
0
0
0
American Depositary Shares
2022-05-24
4
P
0
400
2.89
A
1400
D
American Depositary Shares
2022-05-24
4
P
0
33
2.76
A
1433
D
Option to Purchase American Depositary Shares
3.53
2022-03-07
4
A
0
6820
0
A
2032-03-07
American Depositary Shares
6820
6820
D
Option to Purchase American Depositary Shares
27.26
2021-04-19
4
A
0
11884
0
A
2031-04-19
American Depositary Shares
11884
11884
D
Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer.
Includes the previously reported 1,000 ADSs of the Company, as reported by Mr. Joel Maryles on Form 4 filed with the SEC on March 21, 2022.
No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only.
These options vest and become exercisable in their entirety on March 16, 2023.
These options vest and become exercisable in equal monthly installments over a 36 month period commencing on March 16, 2021, subject to the Reporting Person's continued service.
/s/ David S. Glatt, Esq., Attorney-in-Fact for Joel Michael Maryles
2022-05-25